SUPN News and Press, Supernus Pharmaceuticals Inc. From 12/27/23

2023-12-27 14:35:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

MONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Supernus"), a biopharm...

2023-12-12 10:33:17 ET More on AbbVie, Evolus, etc. AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth AbbVie upgraded at Goldman ...

2023-11-10 14:22:53 ET Summary Supernus Pharmaceuticals has experienced revenue growth every year since its IPO in 2021, reaching $667m in 2022. The company has expanded its product portfolio through acquisitions, including the purchase of Adamas for $850m. Q3 earnings beat ex...

2023-11-08 19:38:01 ET Supernus Pharmaceuticals, Inc. (SUPN) Q3 2023 Earnings Conference Call November 08, 2023 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial ...

2023-11-08 16:39:44 ET More on Supernus Pharmaceuticals Supernus: Product Sales Stretching Higher, But Not Reflected In Economic Leverage Supernus Pharmaceuticals Q3 2023 Earnings Preview Supernus resubmits NDA for Parkinson's disease infusion device Seeking ...

Raises full year 2023 adjusted operating earnings (non-GAAP) (1) guidance range to $95 million to $110 million from previous range of $75 million to $100 million Total revenues (GAAP) of $153.9 million in the third quarter of 2023; total revenues excluding Trokendi XR ® net produ...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Supernus Pharmaceuticals Inc. (SUPN) is expected to report $0.13 for Q3 2023

2023-11-07 17:35:55 ET More on Supernus Pharmaceuticals Supernus: Product Sales Stretching Higher, But Not Reflected In Economic Leverage Supernus resubmits NDA for Parkinson's disease infusion device EU regulators warn pregnant women not to use topiramate Se...